Loading patent…
AssigneesSchool Corporation, Azabu Veterinary Medicine Educational Institution, Tella, Inc.
InventorsTadashi YAMASHITA, Masaki NAGANE, Teruo IKEDA, Shoichiro MIYATAKE, Mariko OKAMOTO
Estimating the term…
The prevent invention provides an activated T cell in which the expression of an immune checkpoint molecule is suppressed, a method for producing the T cell, and a method for screening for a substance that can be used in the production of the T cell. Specifically, the prevent invention includes, as solving means, a method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, the method comprising reducing or losing the function of UDP-glucose ceramide glucosyltransferase (UGCG) or ganglioside in a T cell, and a T cell produced or induced by the aforementioned method.
A method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, the method comprising reducing or losing the function of UDP-glucose ceramide glucosyltransferase (UGCG) or ganglioside in a T cell.
A T cell comprising UGCG whose function is reduced or lost, in which an increase in the expression of an immune checkpoint molecule by activation is not induced.
An immune checkpoint inhibitor comprising a UGCG inhibitor as an active ingredient.
An agent for suppressing the expression of PD-1, TIM3, and/or CTLA4 in a T cell, the agent comprising a UGCG inhibitor as an active ingredient.
An agent for maintaining the activation of a T cell, the agent comprising a UGCG inhibitor as an active ingredient.
A method for screening for an immune checkpoint-inhibiting substance, comprising
A method for screening for an immune checkpoint-inhibiting substance, comprising:
Dependencies are inferred from the claim text.